Published in Int J Immunopharmacol on January 01, 1991
Comparisons of pKa and log P values of some carboxylic and phosphonic acids: synthesis and measurement. AAPS PharmSci (2001) 0.75
Effects of activated complement components on enzyme secretion by macrophages. Immunology (1976) 2.63
Ability of activated complement components to induce lysosomal enzyme release from macrophages. Nature (1976) 1.85
Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway of complement. Arthritis Rheum (1977) 1.82
Complement activation by the alternative pathway and macrophage enzyme secretion in the pathogenesis of chronic inflammation. Immunology (1977) 1.82
Ability of the T cell-replacing polyanion dextran sulfate to trigger the alternate pathway of complement activation. Eur J Immunol (1973) 1.68
Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology (1993) 1.56
Interaction of C3b, B, and D in the alternative pathway of complement activation. J Immunol (1975) 1.55
Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects. Clin Exp Immunol (1978) 1.46
DNP-antigens activate the alternate pathway of the complement system. J Immunol (1974) 1.44
Activation by some T-independent antigens and B cell mitogens of the alternative pathway of the complement system. J Immunol (1975) 1.39
Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas. Eur J Nucl Med (1988) 1.32
Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer (1999) 1.31
Cefodizime, an aminothiazolyl cephalosporin. IV. Influence on the immune system. J Antibiot (Tokyo) (1984) 1.25
Expression of Clarkia S-linalool synthase in transgenic petunia plants results in the accumulation of S-linalyl-beta-D-glucopyranoside. Plant J (2001) 1.25
The selective release of lysosomal acid hydrolases from mouse peritoneal macrophages by stimuli of chronic inflammation. Br J Exp Pathol (1977) 1.22
Cytolytic effects of the complement cleavage product, C3a. Br J Cancer (1976) 1.22
Dextran sulphate: a synthetic activator of C3 via the alternative pathway. I. Influence of molecular size and degree of sulphation on the activation potency. Immunology (1975) 1.22
Macrophage responses to mouldy hay dust, Micropolyspora faeni and zymosan, activators of complement by the alternative pathway. Clin Exp Immunol (1977) 1.21
Interactions between Entamoeba histolytica and complement. Nature (1979) 1.18
Difficulty in removal of accidentally cut endotracheal tube. J Oral Maxillofac Surg (1982) 1.14
Factor D in the alternate pathway of complement activation: purification, physicochemical characterization and functional role. Immunochemistry (1974) 1.09
Further link between complement activation and blood coagulation. Nature (1977) 1.09
Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions (1991) 1.05
Macrophage secretion and the complement cleavage product C3a in the pathogenesis of infections by mycoplasmas and L-forms of bacteria and in immunity to these organisms. Clin Exp Immunol (1978) 1.01
Induction of lysosomal enzyme release from cultured macrophages by dextran sulfate. Clin Immunol Immunopathol (1977) 0.99
Antigen-specific detection of HBsAG-containing immune complexes in the course of hepatitis B virus infection. Clin Exp Immunol (1979) 0.98
Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc (1991) 0.98
Cholera toxin induced redistribution of sialoglycolipid receptor at the lymphocyte membrane. FEBS Lett (1976) 0.97
15-Deoxyspergualin for induction of graft nonreactivity after cardiac and renal allotransplantation in primates. Transplantation (1990) 0.96
The influence of (+/-)-15-deoxyspergualin on experimental transplantation and its immunopharmacological mode of action. Behring Inst Mitt (1986) 0.96
The role of macrophage activation in chronic inflammation. Agents Actions (1978) 0.95
Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. Eur J Immunol (1994) 0.94
Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable on carcinoembryonic antigen (CEA). Int J Cancer (1985) 0.93
Microvascular phenomena during pancreatic islet graft rejection. Langenbecks Arch Chir (1991) 0.93
[Chilaiditi's syndrome complicated by subdiaphragmatic perforated appendicitis: unusual manifestation of a rare condition]. Chirurg (2011) 0.92
Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther (2000) 0.91
Cartilage specific collagen activates macrophages and the alternative pathway of complement: evidence for an immunopathogenic concept of rheumatoid arthritis. Ann Rheum Dis (1982) 0.91
Temporal sequence of pulmonary and systemic inflammatory responses to graded polymicrobial peritonitis in mice. Infect Immun (1999) 0.91
Comparative study on biological effects of the guinea pig complement-peptide C3a and C3a-related synthetic oligopeptides. Mol Immunol (1980) 0.90
[The current status of scintigraphy of the cervical lymphatic system]. Nucl Med (Stuttg) (1967) 0.90
A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. I. Immunohistological and immunochemical characterization of a murine monoclonal antibody selecting for well differentiated adenocarcinomas of the pancreas. Cancer Immunol Immunother (1986) 0.89
Activation of complement by the alternative pathway as a factor in the pathogenesis of periodontal disease. Lancet (1976) 0.88
Metabolic fate of isotopes during the biological transformation of carbohydrates to 2,5-dimethyl-4-hydroxy-3(2h)-furanone in strawberry fruits. J Agric Food Chem (2001) 0.87
Epstein-Barr virus related hemophagocytic syndrome in a T-cell rich B-cell lymphoma. Ann Oncol (1999) 0.87
Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br J Cancer (1992) 0.87
Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins. J Med Chem (1999) 0.87
Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis. J Med Chem (1999) 0.86
Immunomodulation by the new synthetic thiazole derivative tiprotimod. 1st communication: synthesis and structure-activity relationships. Arzneimittelforschung (1989) 0.86
The biological properties of immunoglobulin G and its split products [F(ab')2 and Fab]. Klin Wochenschr (1983) 0.85
Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells. Int J Cancer (1998) 0.84
Effects of elevating the head of bed on interface pressure in volunteers. Crit Care Med (2008) 0.84
Antigen-specific detection of soluble immune complexes by a solid phase specific antibody system. J Immunol Methods (1979) 0.84
Chemotherapeutically active nitro compounds. 4. 5-Nitroimidazoles (Part I). Arzneimittelforschung (1977) 0.84
Biochemical properties of recombinant human beta-glucuronidase synthesized in baby hamster kidney cells. Biochem J (1994) 0.84
Autoreactivity to mouse C1q in a murine model of SLE. Rheumatol Int (1995) 0.83
Monoclonal antibodies against CEA-related components discriminate between pancreatic duct type carcinomas and nonneoplastic duct lesions as well as nonduct type neoplasias. Virchows Arch A Pathol Anat Histopathol (1986) 0.83
Effect of Vibrio cholerae neuraminidase on the phagocytosis of E. coli by macrophages in vivo and in vitro. Immunology (1978) 0.83
Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci (1998) 0.83
Regression of spontaneous mammary tumors in dogs after injection of neuraminidase-treated tumor cells. Int J Cancer (1975) 0.82
2,5-Dimethyl-4-hydroxy-3[2H]-furanone 6'O-malonyl-beta-D-glucopyranoside in strawberry fruits. Phytochemistry (1996) 0.82
Suppression of macrophage function and prolongation of graft survival by the new guanidinic-like structure, 15-deoxyspergualin. Transplant Proc (1987) 0.82
Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplant Proc (1996) 0.82
Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes. Cancer Res (1983) 0.82
Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy. Br J Cancer (1991) 0.81
Stimulation of cell-mediated immunity by bestatin correlates with reduction of bacterial persistence in experimental chronic Salmonella typhimurium infection. Infect Immun (1984) 0.81
[New and changed guidelines in the TNM system of head and neck tumors]. HNO (1987) 0.81
Structure-activity relationship of anthracyclines in vitro. J Med Chem (1990) 0.80
Metabolic profile of linoleic acid in stored apples: formation of 13(R)-hydroxy-9(Z),11(E)-octadecadienoic acid. Lipids (1999) 0.80
[Past and current problems in tumor research]. Dtsch Med Wochenschr (1986) 0.80
Similarities in function between pancreatic tumor cells and macrophages and their inhibition by murine monoclonal antibodies. Behring Inst Mitt (1988) 0.80
Decrease of mononuclear phagocyte cell functions and prolongation of graft survival in experimental transplantation by (+/-)-15-deoxyspergualin. Int J Immunopharmacol (1987) 0.80
The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats. Scand J Immunol (1992) 0.80
Case Reports. Chronic and acute Aspergillus meningitis. Mycoses (2002) 0.80
Monoclonal antibodies against epitopes on ganglioside GD2 and its lactones. Markers for gliomas and neuroblastomas. Cancer Immunol Immunother (1989) 0.80
Stimulatory effect of Vibrio cholerae neuraminidase on the antibody response to various antigens. Immunology (1978) 0.80
Characterization of lymphocyte subpopulations of nonhuman primates separated by free-flow electrophoresis. Transplant Proc (1974) 0.79
In vivo labelling of granulocytes with 99mTc anti-NCA monoclonal antibodies for imaging inflammation. Eur J Nucl Med (1988) 0.79
[Pfeifer-Weber-Christian syndrome of the mesentery. Clinical and pathologico-anatomical aspects]. Acta Med Austriaca (1983) 0.79
[Current remarks for use of the TNM classification on head and neck (author's transl)]. Laryngol Rhinol Otol (Stuttg) (1975) 0.78
2,5-Dimethyl-4-hydroxy-3(2H)-furanone as a secondary metabolite from D-fructose-1,6-diphosphate metabolism by Zygosaccharomyces rouxii. J Biosci Bioeng (2001) 0.78
Pelvic crush injuries with occlusion of the iliac artery. J Trauma (1988) 0.78
Characteristics of cytotoxic antibodies against neuraminidase-treated lymphocytes in man. J Natl Cancer Inst (1979) 0.78
Identification of 2,5-dimethyl-4-hydroxy-3[2H]-furanone beta-D-glucuronide as the major metabolite of a strawberry flavour constituent in humans. Food Chem Toxicol (1997) 0.78
The use of computerized axial tomography versus peritoneal lavage in the evaluation of blunt abdominal trauma: a prospective study. Surgery (1985) 0.78
Demonstration of high-affinity binding sites for C3a anaphylatoxin on guinea-pig platelets. Scand J Immunol (1978) 0.78
Neuraminidase and tumor immunotherapy. Klin Wochenschr (1977) 0.78
Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin. Clin Exp Immunol (1993) 0.78
Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems. Behring Inst Mitt (1984) 0.77
Nuclear fragmentation of high-energy heavy-ion beams in water. Adv Space Res (1996) 0.77
Imaging of inflammation with granulocytes labelled in vivo. Nucl Med Commun (1988) 0.77